Vigadrone Powder, For Solution
Product Images NDC 0245-0556

Product Visual Gallery

This gallery contains 17 technical images submitted to the FDA as part of the official labeling for Vigadrone (NDC 0245-0556). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Upsher-smith Laboratories, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

The Structural Formula For Vigabatrin, A Racemate Consisting Of Two Enantiomers, Is (±) 4 Amino-5 Hexenoic Acid. The Molecular Formula Is C6h11no2 And The Molecular Weight Is 129.16. (Vigadrone 01)

Chemical structure of vigabatrin, the active ingredient in VIGADRONE oral powder for solution 50 mg/mL by Upsher-Smith Laboratories, LLC. The diagram depicts the molecular structure including an amino group and a carboxyl group.*

FDA Label Image

Figure 1. percent Reduction From Baseline In Seizure Frequency (Vigadrone 02)

A cumulative distribution plot showing percent reduction in seizure frequency on the vertical axis against percent of patients on the horizontal axis. The graph compares placebo and three different dosages of vigabatrin (1g/day, 3g/day, 6g/day) with labels indicating improvement (up) and worsening (down) of seizure frequency.*

FDA Label Image

Figure 2. percent Reduction From Baseline In Seizure Frequency (Vigadrone 03)

A line graph showing percent reduction in seizure frequency versus percent of patients for Vigabatrin (3 g/day) compared to placebo. The vertical axis represents changes in seizure frequency from worsening (-100%) to improvement (+100%), with a horizontal line marking no change. Two curves illustrate patient response distributions for Vigabatrin and placebo groups.*

FDA Label Image

All People Who Take Vigadrone (Vigadrone 04)

A text panel titled 'All people who take VIGADRONE' providing warnings about the risk of permanent vision loss associated with VIGADRONE use. It explains that any amount of the drug can cause this risk, that the risk increases with dose and duration, and that vision loss timing is unpredictable, possibly occurring during or after treatment.*

FDA Label Image

Supplies You Will Need To Mix 1 Dose Of Vigadrone: (Vigadrone 05)

An instructional illustration showing the preparation of VIGADRONE, vigabatrin powder for solution. The image includes a VIGADRONE powder packet, a glass of water with a spoon, a syringe, and scissors, suggesting steps to mix the powder with water for oral administration.*

FDA Label Image

Oral Syringe Detail (Vigadrone 06)

Illustration labeled 'Oral syringe detail' showing parts of an oral syringe used for dosing. Key components identified include the tip, dosage indicators on the barrel, the barrel itself, the plunger, and the bottom of the white plunger.*

FDA Label Image

Figure A (Vigadrone 07)

An illustration labeled Figure A showing a hand holding a vial of VIGADRONE (vigabatrin) powder, pouring its contents into a glass container, demonstrating preparation of the oral solution from the powder form.*

FDA Label Image

Figure B (Vigadrone 08)

Figure B shows two clear glass cups placed side by side on a light surface against a neutral background. One cup contains a clear liquid, while the other cup is empty, illustrating a step or concept related to the product's oral powder for solution form.*

FDA Label Image

Figure C (Vigadrone 09)

An instructional illustration labeled Figure C showing a hand holding a container and dipping a powder packet or stick into a glass of water, demonstrating preparation of an oral powder solution.*

FDA Label Image

Figure D (Vigadrone 0a)

An instructional illustration showing a hand holding a syringe, likely demonstrating the process of measuring or preparing a dose of oral solution, relevant to the usage of VIGADRONE (vigabatrin) powder for solution, 50 mg/mL.*

FDA Label Image

Figure E (Vigadrone 0b)

An instructional illustration labeled 'Figure E' showing a close-up of a syringe with measurement markings. The image highlights the 10 mL line on the syringe with an arrow pointing to it. This diagram is likely part of dosing or reconstitution instructions for the drug Vigadrone (vigabatrin) powder for solution, oral.*

FDA Label Image

Figure F (Vigadrone 0c)

An instructional illustration labeled as Figure F showing a hand holding a syringe being placed into a clear glass, likely demonstrating the preparation of VIGADRONE oral powder for solution by drawing liquid into the syringe from the glass.*

FDA Label Image

Figure G (Vigadrone 0d)

Instructional illustration showing a hand holding a spoon above an empty glass, labeled as Figure G. The image likely relates to the preparation or administration of an oral solution.*

FDA Label Image

Figure H (Vigadrone 0e)

An instructional illustration labeled Figure H showing a hand holding a syringe or dropper inside a clear glass container. The image likely demonstrates a step related to preparing or measuring a dose of a liquid solution.*

FDA Label Image

Figure I (Vigadrone 0f)

An instructional illustration labeled Figure 1 showing a hand holding an oral dosing syringe. The syringe is marked with measurement lines for precise liquid dosing.*

FDA Label Image

Figure J (Vigadrone 10)

An instructional illustration labeled Figure J showing an infant receiving an oral dose of medication via an oral syringe. The syringe is positioned at the infant's mouth, demonstrating proper administration of the oral powder for solution dosage form.*

FDA Label Image

Ndc 0245-0556-50vigadrone® (vigabatrin) For Oral Solution500 mg50 Single-dose Packetsrx Only (Vigadrone 11)

VIGADRONE 500 mg powder for oral solution packaging label. The label indicates the active ingredient vigabatrin and displays the dosage strength of 500 mg. It is supplied in 50 single-dose packets and is labeled Rx only. The manufacturer is Upsher-Smith Laboratories, LLC with product NDC 0245-0556.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.